Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dyadic International, Inc. - Common Stock (NQ:DYAI)

0.8713 +0.0449 (+5.43%)
Streaming Delayed Price Updated: 10:16 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dyadic International, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
From Dyadic International, Inc.
Via GlobeNewswire
Healthcare Undervalued Opportunities Poised for Growth: DYAI, INBS, VTAK, RSCI, VERO, MRVI
Via AB Newswire
Dyadic International Inc. (NASDAQ: DYAI) Surges 19.2% Amid Robust Trading Volume Following Expanded Collaboration with Israeli Institutes
Via AB Newswire
Latest Buzz on The Street: Noteworthy Developments at DYAI, ELEV, ATRA, ESPR, KAVL
Via AB Newswire
News headline image
Recap: Dyadic International Q3 Earnings ↗
 
Via Benzinga
News headline image
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
Nasdaq Stocks Are Taking Center Stage This Week! DYAI, MRVI, SPWR, VTAK, KAVL, INBS
Via AB Newswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
Biopharmaceutical Advancements: Dyadic (Nasdaq: DYAI) Raises Industry Standards with Maravai LifeSciences’ (Nasdaq: MRVI) Cygnus Technologies
Via AB Newswire
News headline image
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
From Dyadic International, Inc.
Via GlobeNewswire
Breaking Ground in BioPharma: Spotlight Companies DYAI, INBS, SANA, IOVA, BLUE
Via AB Newswire
News headline image
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
From Dyadic International, Inc.
Via GlobeNewswire
Top 5 Active Stock Buzzers Under $10: INBS, PLUG, KOPN, DYAI, MINM
Via AB Newswire
News headline image
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
From Dyadic International, Inc.
Via GlobeNewswire
“Revolutionizing Biotechnology: Dyadic International (NASDAQ: DYAI) Leads with C1 Platform for Swift and Efficient Protein Production”
Via AB Newswire
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI
Via AB Newswire
“Dyadic International Inc. (NASDAQ: DYAI): Zacks Small-Cap Research Indicates Valuation at $9.00 per Share”
Via AB Newswire
“Dyadic International (NASDAQ: DYAI) Revolutionizing Pharma with Innovative C1 Technology for Global Protein Development”
Via AB Newswire
News headline image
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
From Dyadic International, Inc.
Via GlobeNewswire
“2024 Market Outlook: SmallCap Radar Stocks Unveiled”: DYAI, SKYX, QUBT, KNW, VTAK
Via AB Newswire
Topics Intellectual Property
“Dyadic International Inc. (NASDAQ: DYAI) Advances Biopharmaceutical Innovations and Vaccine Manufacturing Globally”
Via AB Newswire
CryptoNewsBreaks – Innovators and Ideas Showcased at 12th Annual Benchmark Discovery Conference
Via Investor Brand Network
InvestorNewsBreaks – Standouts from 12th Annual Benchmark Discovery Conference Featured in Nasdaq Article
Via Investor Brand Network
News headline image
Dyadic Attends Investor Events in December
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic to Present at Industry Events in November
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
From Dyadic International, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.